Emerging drugs bring a positive shift in Globa...

Osteoporosis, recognized as one of the most severe global burdens, is the reason behind more than 8.9 million fractures annually, resulting in an osteoporotic fracture every 3 seconds globally.FDA recently has permitted the new drug application (NDA) for Bonsity (PF708) for the treatment of osteoporosis. Submitted ...

The World Health Organization’s disability rating for migraine ranks it as the 19th most common reason for disability. According to the Migraine Trust Organization, Migraine is ranked as the 7th most disabling disease in the world (a cause for a loss of 2.9% of all years of life lost to disability/YLDs). The ...

Peanut allergies (PA) are the most common and severe type of food allergies in children. Even a small fragment of this legume to an allergic person can result in permanent brain damage.  The prevalence rate of the Peanut allergy, over the past two decades, has tripled. According to DelveInsight, total prevalen...

The US FDA has in a recent move granted Roche’s Gazyva Breakthrough Therapy Designation (BTD) for adults with lupus nephritis. Gazyva (obinutuzumab) is an anti-cancer ("antineoplastic" or "cytotoxic") chemotherapy drug. Classified as a "monoclonal antibody", Gazyva is a CD20-directed cytolytic antibody. The drug...

More than a dozen companies have shifted their focus towards the Hormone Receptor positive (HR+), human epidermal growth factor receptor 2 (HER2) negative breast cancer therapeutic area. Some of them are Jiangsu HengRui Medicine Co., Odonate Therapeutics, Radius Pharmaceuticals, Immunomedics, Roche Group Syndax Ph...

Hormone Receptor (HR)-positive/ Human Epidermal Receptor 2 (HER2)-negative Breast Cancer is the most prevalent form of breast cancer. This type accounts for a higher percentage among all breast cancers. Hormone receptors are proteins that receive hormone signals and cue the cancer cells to grow. If breast cancer ce...